Abstract
TPS3132 Background: We have reported promising activity, including one RECIST PR and potential synergy with chemotherapy, in a phase I trial of 18 men with mCRPC administered BPX-101 (Bellicum Phar...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
